Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Sarcoma 1Liposarcoma 1Leukemia, Hairy Cell 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cisplatin 15pembrolizumab 14Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 10Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Paclitaxel 7durvalumab 6Radiotherapy, Intensity-Modulated 6Cetuximab 6cemiplimab 5Radiotherapy 5Radiation 5Pemetrexed 5Nivolumab 5Biopsy 5Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3atezolizumab 3Taxes 3Oxaliplatin 3Docetaxel 3ipatasertib 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Famotidine × 90 days × Clear all
NCT05977998 2026-05-22

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡